ViewRay, Inc. (VRAY)
| Market Cap | 699.15M |
| Revenue (ttm) | 55.03M |
| Net Income (ttm) | -117.02M |
| Shares Out | 148.04M |
| EPS (ttm) | -0.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $4.36 |
| Previous Close | $4.48 |
| Change ($) | -0.12 |
| Change (%) | -2.68% |
| Day's Open | 4.50 |
| Day's Range | 4.36 - 4.74 |
| Day's Volume | 1,169,613 |
| 52-Week Range | 1.11 - 7.36 |
STOCKHOLM, Jan. 22, 2021 /PRNewswire/ -- Elekta AB (EKTA-B.ST) announced today that it has sold its 7.3 percent of the outstanding common stock (11,501,597 shares) in ViewRay, Inc. (Nasdaq:VRA...
CLEVELAND, Jan. 15, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) (the "Company") today announced that members of management will be participating in a fireside chat at the B. Riley Oncolo...
The company announced the pricing of a public offering of common stock.
CLEVELAND, Jan. 7, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer pati...
CLEVELAND, Jan. 4, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer pati...
CLEVELAND, Jan. 4, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer pati...
CLEVELAND, Ohio, Jan. 4, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced preliminary results for the fourth quarter and full fiscal year ended December 31, 2020. The prelimin...
CLEVELAND, Dec. 23, 2020 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced its participation in the 39th Annual J.P. Morgan Healthcare Conference. Scott Drake, President and CEO, is...
CLEVELAND, Dec. 22, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the clinical team at Seoul National University Hospital (SNUH), a leading healthcare facility in Sout...
CLEVELAND, Dec. 21, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Catharina Hospital in Eindhoven, Netherlands, also known as Catharina Ziekenhuis, has purchased a MRI...
CLEVELAND, Nov. 12, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the clinical team at Amsterdam University Medical Centers (Amsterdam UMC) has treated one thousand pa...
CLEVELAND, Nov. 10, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Universitair Ziekenhuis Brussels has purchased a MRIdian® Linac MRI-Guided Therapy System, a cutting-...
ViewRay, Inc. (VRAY) CEO Scott Drake on Q3 2020 Results - Earnings Call Transcript
ViewRay (VRAY) delivered earnings and revenue surprises of -11.76% and 13.15%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
ViewRay (VRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CLEVELAND, Oct. 21, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's MRIdian® Linac MRI-guided radiation therapy system will be featured at the 2020 Annual ...
CLEVELAND, Oct. 14, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the Louis Stokes Cleveland VA Medical Center in Cleveland, Ohio has purchased the MRIdian® Linac MRI-...
ViewRay (VRAY) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
CLEVELAND, Sept. 24, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Chungnam National University Sejong Hospital in Sejong, South Korea has begun patient treatments wit...
CLEVELAND, Sept. 4, 2020 /PRNewswire/ -- ViewRay, Inc.
CLEVELAND, Sept. 1, 2020 /PRNewswire/ -- ViewRay, Inc.
CLEVELAND, Aug. 13, 2020 /PRNewswire/ -- ViewRay, Inc.
CLEVELAND, Aug. 5, 2020 /PRNewswire/ -- ViewRay, Inc.
ViewRay's (VRAY) CEO Scott Drake on Q2 2020 Results - Earnings Call Transcript
ViewRay (VRAY) delivered earnings and revenue surprises of -12.50% and 144.95%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
CLEVELAND, July 30, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the second quarter ended June 30, 2020.
ViewRay (VRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength in MRIdian system business is likely to have aided ViewRay's (VRAY) performance in second-quarter 2020 amid the coronavirus-led economic doldrums.
CLEVELAND, July 13, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its second quarter 2020 financial results. ViewRay will hold a conferen...
Despite market's roller-coaster ride, a handful of momentum stocks with a favorable Zacks Rank have provided double-digit returns so far in June.
Top Ranked Momentum Stocks to Buy for June 23rd
CLEVELAND, June 3, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today grants of stock options and restricted stock units to Zach Stassen, Chief Financial Officer for the company...
CLEVELAND, May 27, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Providence Portland Medical Center in Portland, Oregon has begun patient treatments with the MRIdian® ...
ViewRay's (VRAY) CEO Scott Drake on Q1 2020 Results - Earnings Call Transcript
ViewRay (VRAY) delivered earnings and revenue surprises of 0.00% and 14.24%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
ViewRay (VRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Economic activities came almost to a standstill in March. However, one sector that witnessed heightening activities is health care.
ViewRay's Inc.'s (VRAY) CEO Scott Drake on Q4 2019 Results - Earnings Call Transcript
ViewRay (VRAY) delivered earnings and revenue surprises of -24.00% and -3.41%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
ViewRay (VRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Shares plunge after the company announces preliminary quarterly results that came up short.
Shares jump after the company announces a pair of collaborations and a capital raise. Here are the key details.
ViewRay's (VRAY) collective investments from Elekta and Medtronic are conditioned to the consummation of an equity capital hike of at least $75 million.
Investors need to pay close attention to ViewRay (VRAY) stock based on the movements in the options market lately.
ViewRay's (VRAY) CEO Scott Drake on Q3 2019 Results - Earnings Call Transcript
ViewRay (VRAY) delivered earnings and revenue surprises of 22.22% and 0.35%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Written by: Craig Adeyanju | FinScreener Penny stocks, on the surface, look attractive because they generally have prices under $5. However, many penny stocks belong in that category for a rea...
Shares rally after management gives investors a sneak peek at its third-quarter results.
About VRAY
ViewRay designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image guided radiation therapy system to image and treat cancer patients. Its MRIdian integrates MRI technology, radiation delivery, and proprietary software to see the soft tissues, shape the dose to accommodate for changes in anatomy, and strike the target using real-time targeting throughout the treatment. The company serves university research and teaching hospitals, community hospitals, private practices, government instit... [Read more...]
| Industry Medical Devices | Founded 2004 |
| CEO Scott William Drake | Employees 309 |
| Stock Exchange NASDAQ | Ticker Symbol VRAY |
Financial Performance
In 2019, ViewRay's revenue was $87.78 million, an increase of 8.42% compared to the previous year's $80.96 million. Losses were -$120.20 million, 57.3% more than in 2018.
Analyst Forecasts
According to 8 analysts, the average rating for ViewRay stock is "Buy." The 12-month stock price forecast is 5.88, which is an increase of 34.86% from the latest price.